Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

M Kawaguchi-SuzukiF BrilS KalavalapalliK CusiReginald F Frye

Published in: Alimentary pharmacology & therapeutics (2017)

This study demonstrates the importance of pioglitazone exposure to variable response in patients with NASH, and indicates potential factors that may identify patients most likely to benefit from chronic pioglitazone treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported